Patient-reported outcome assessment in heart failure with preserved ejection fraction: A systematic review of semaglutide trials using the Kansas City Cardiomyopathy Questionnaire

doi:10.13105/wjma.v14.i2.121918

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

(5)

(8)

(0)

(2)

(104)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Meta-Anal. Jun 18, 2026; 14(2): 121918
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.121918

Table 1 Characteristics and key outcomes of included studies

Ref.	Study design	n (sema/control)	Semaglutide dose	Follow-up	Mean age (years)	Women (%)	Mean BMI (kg/m²)	Diabetes at baseline	Mean LVEF (%)	Primary PRO endpoint	Baseline KCCQ score	KCCQ treatment effect	Pooled RCT effect (fixed-effects)	Blinding status	Risk of bias (tool)	Population	Sponsorship
Kosiborod et al[4]	Double-blind RCT	263/266	2.4 mg SC weekly	52 weeks	69	56	37	Excluded	57	KCCQ-CSS	CSS 60 pts	+7.8 pts (95%CI: 4.8-10.9)	7.36 pts (95%CI: 5.32-9.40; I² = 0%)	Double-blind	Low (RoB 2)	White, Western, BMI ≥ 30	Industry (Novo Nordisk)
Kosiborod et al[5]	Double-blind RCT	310/306	2.4 mg SC weekly	52 weeks	69	45	37	Required (T2D)	55	KCCQ-CSS	CSS 60 pts	+7.0 pts (95%CI: 4.3-9.8)	7.36 pts (95%CI: 5.32-9.40; I² = 0%)	Double-blind	Low (RoB 2)	White, Western, BMI ≥ 30	Industry (Novo Nordisk)
Pérez-Velasco et al[6]	Prospective cohort (PSM)	203/203	0.5-1.0 mg SC weekly	24 months	76	59	35	Required (T2D)	≥ 50	KCCQ-TSS	TSS 54 pts	+14 pts between-group	NA (excluded from pooling)	Open-label	Moderate-to-high (ROBINS-I)	Spanish, BMI ≥ 30, T2D	Not explicitly reported

BMI: Body mass index; CSS: Clinical Summary Score; HFpEF: Heart failure with preserved ejection fraction; KCCQ: Kansas City Cardiomyopathy Questionnaire; LVEF: Left ventricular ejection fraction; PRO: Patient-reported outcome; PSM: Propensity score matching; RCT: Randomised controlled trial; SC: Subcutaneous; T2D: Type 2 diabetes mellitus; TSS: Total Symptom Score; RoB 2: Risk of Bias 2; NA: Not available.

Full Size Table

Citation: Abdulaal R, Khalil LM, Hteit A, Al Mashtoub E, Allaw M, Hajj L, Taki A, Tlais M. Patient-reported outcome assessment in heart failure with preserved ejection fraction: A systematic review of semaglutide trials using the Kansas City Cardiomyopathy Questionnaire. World J Meta-Anal 2026; 14(2): 121918
URL: https://www.wjgnet.com/2308-3840/full/v14/i2/121918.htm
DOI: https://dx.doi.org/10.13105/wjma.v14.i2.121918

Abdulaal R, Khalil LM, Hteit A, Al Mashtoub E, Allaw M, Hajj L, Taki A, Tlais M. Patient-reported outcome assessment in heart failure with preserved ejection fraction: A systematic review of semaglutide trials using the Kansas City Cardiomyopathy Questionnaire. World J Meta-Anal 2026; 14(2): 121918 [DOI: 10.13105/wjma.v14.i2.121918]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.